Skip to content

A real life experience about the effectiveness of Upadacitinib and its side effects profile in moderate to severe crohns disease patient who didnot respond or are intolerant to conventional therapy or biologics therapy from a single centre

Upadacitinib in moderate to severe crohns disease who have failed or are intolerant to conventional therapy or biologics therapy: a real world experience from a single tertiary centre - nil

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106766
Enrollment
92
Registered
2026-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K509- Crohns disease, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

IPGMER, Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: male and female with confirmed diagnosis of crohns disease. with inadequate response or intolerant to one or more conventional therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Achievement of clinical remissionas as per CDAITimepoint: Week 12

Secondary

MeasureTime frame
acheivement of clinical response as per CDAITimepoint: week 12;maintenance of clinical remission/ reponseTimepoint: 6 months;acheivement of clinical remission as per PROTimepoint: 12 weeks and 6 months;Discontinuation of corticosteroid use for CD per CDAI ( subjects taking corticosteroids for CD at Baseline)Timepoint: week 12;Resolution of draining fistula (subjects with draining fistulas at BaselineTimepoint: week 24;t least 50% decrease from Baseline in the number of days with very soft or liquid stools (Type 6 or 7, per Bristol Stool Chart) during the last 7 days at or 50% decrease in baseline in the pain scoreTimepoint: week 12 and 6 months;High sensitivity C-reactive protein (hs-CRP)Timepoint: week 12 and 6 months

Countries

India

Contacts

Public ContactDr Sumeet chatterjee

IPGMER, Kolkata

drrajibsarkar@yahoo.com9477371103

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026